Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PIRS

Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis

Pieris Pharmaceuticals logo

About Pieris Pharmaceuticals Stock (NASDAQ:PIRS)

Key Stats

Today's Range
$13.26
$15.35
50-Day Range
$13.60
$17.07
52-Week Range
$12.63
$18.68
Volume
51,728 shs
Average Volume
90,136 shs
Market Capitalization
$17.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PIRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PIRS Stock News Headlines

Pieris Pharmaceuticals Inc
Palvella Therapeutics Inc (PVLA)
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.tc pixel
One new option listing and one option delisting on December 16th
See More Headlines

PIRS Stock Analysis - Frequently Asked Questions

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) issued its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($19.20) EPS for the quarter, meeting analysts' consensus estimates of ($19.20). The biotechnology company had revenue of $4.06 million for the quarter, compared to analysts' expectations of $7.98 million. Pieris Pharmaceuticals had a negative net margin of 39.71% and a negative trailing twelve-month return on equity of 80.93%.

Pieris Pharmaceuticals shares reverse split on the morning of Tuesday, April 23rd 2024.The 1-80 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pieris Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Adobe (ADBE), GE Aerospace (GE) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/02/2021
Today
9/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PIRS
CIK
1583648
Employees
140
Year Founded
2001

Profitability

EPS (Trailing Twelve Months)
($12.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$24.54 million
Net Margins
-39.71%
Pretax Margin
-1,179.96%
Return on Equity
-80.93%
Return on Assets
-59.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.82
Quick Ratio
4.82

Sales & Book Value

Annual Sales
$42.81 million
Price / Sales
0.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$21.66 per share
Price / Book
0.63

Miscellaneous

Outstanding Shares
1,320,000
Free Float
1,236,000
Market Cap
$17.95 million
Optionable
Optionable
Beta
0.61

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:PIRS) was last updated on 9/23/2025 by MarketBeat.com Staff
From Our Partners